Response 816782146

Back to Response listing

About you

1. What is your name?

Name
Rosalie Schultz

3. Which of the following best describes you?

Please select one item
(Required)
Radio button: Unticked Medicine sponsor/manufacturer/wholesaler representative organisation
Radio button: Unticked Health professional representative organisation
Radio button: Unticked Consumer representative organisation
Radio button: Unticked Government agency
Radio button: Unticked Research/academia/media
Radio button: Unticked Individual sponsor/manufacturer/wholesaler/retailer
Radio button: Ticked Individual health professional, please specify type
Radio button: Unticked Individual consumer/general public/community member
Radio button: Unticked Other, please specify
Other, please specify
GP in Aboriginal community-controlled health service

4. Organisation name:

Organisation name
Ngaanyatjarra Health Service

5. Size of organisation:

Please select one item
Radio button: Unticked Small (20 employees and under)
Radio button: Ticked Medium (20-199 employees)
Radio button: Unticked Large (over 200 employees)

6. Have you been affected by a medicine shortage or discontinuation in the last 12 months?

Please select one item
Radio button: Ticked Yes
Radio button: Unticked No
Radio button: Unticked Unsure

7. If yes, please list which medicine shortage(s) and/or discontinuation(s).

Which shortage
Procaine penicillin
Benzathine penicillin - this is most critical for us, there is no alternative for treatment of syphilis and prevention of rheumatic heart disease
Tenecteplase
Semaglutide
Dulaglutide
Warfarin

Planning for medicine shortages and discontinuations

8. What do you do to plan proactively for a medicine shortage or discontinuation? Select all that apply.

Please select all that apply
Checkbox: Ticked Monitor medicine availability (supply, demand)
Checkbox: Ticked Seek out information about shortages and discontinuations
Checkbox: Ticked Manage stock levels
Checkbox: Ticked Plan for alternative treatments in case of shortage
Checkbox: Ticked Change the way medicine is prescribed/dispensed/taken (e.g. rationing)
Checkbox: Unticked Other

9. Please explain in more detail how you plan proactively for a medicine shortage or discontinuation, including any barriers or challenges you experience.

Prepare: elaborate
We run eight clinics and we can manage stock across clinics. Sometimes clinics hold extra stock based on fluid population numbers and this has enabled us to go through shortages with no impact.

10. [Pharmaceutical companies only] What measures do you use to monitor and predict medicine supply including disruptions and increases in demand? Are there any barriers or challenges?

Prepare: monitor and predict
NA

Responding to medicine shortages and discontinuations

11. Please outline how you respond to a medicine shortage or discontinuation, including any barriers or challenges you experience.

Responding: response
Identify stock
Quantify need and whether there are other options for some indications
Consider alternative options - either standard items or emergency options (eg Orspec Benzathine penicillin)

12. Please describe in detail where any of the following have helped you to respond to a medicine shortage or discontinuation:

Responding: helpful
We have accessed emergency sources of benzathine pencillin to ensure critical need for rheumatic heart disease prevetion and syphilis treatment

Communicating about medicine shortages and discontinuations

13. Where do you get information about a medicine shortage or discontinuation? Select all that apply.

Please select all that apply
Checkbox: Ticked Health professional organisations
Checkbox: Unticked Patient organisations
Checkbox: Ticked Industry organisations
Checkbox: Ticked The TGA and other federal government agencies
Checkbox: Unticked State and territory government agencies
Checkbox: Unticked The media, including social media
Checkbox: Ticked Other sources, please specify
Communicating: information source: other
Our contracted pharmacy

14. What information or updates about a medicine shortage or discontinuation do you find most helpful and from where?

Communicating: information most helpful
Early warning and dates of anticipated shortage
Alternative supplies

15. What challenges do you face when receiving information about medicine shortages or discontinuations?

Communicating: challenges when receiving information
Some shortage never affect us (eg warfarin)
Remote Aboriginal population has distinct need for benzathine penicillin that is not recognised in mainstream

We are at the very end of global supply chains, so when shortages are brief, they do not affect us, but prolonged shortage such as semaglutide is devastating.

16. What challenges do you face when sharing information about medicine shortages or discontinuations?

Communicating: challenges when sharing information
Mobile population

17. What do you think about the information on the TGA website about medicine shortages and discontinuations?

Communicating: TGA website
Clear, unbiased, easy to access, readily available

18. Do you have any suggestions to improve the TGA’s communication of this information?

Communicating: TGA suggestions
Role of TGA vs other agencies needs to be clear

Impact of medicine shortages and discontinuations

19. Over the past 12 months, how much time did you spend on medicine shortages or discontinuations? What activities took the most time?

Impact: time
About 20 hours
Auditing stock
Considering options
Educating staff and patients

20. What were the most challenging activities and why?

Impact: most challenging
ON-going uncertainty about semaglutide

21. Tell us about the health-related impacts of medicine shortages or discontinuations.

Impact: health-related
Declines in quality of diabetes care
increased progression of renal disease in very high risk population. It is likely that renal decline has accelerated in a small number of people who require renal replacement therapy that they would not have needed with adequate supply of semaglutide.
Others face weight gain that may have been prevented.

22. Are there other impacts of medicine shortages and discontinuations that you would like to mention?

Impact: other
Seems inequitable when people who can pay for medication can have on-going access to semaglutide, including those who do not have diabetes.

Improvement opportunities

23. What is the biggest problem within the following areas that you want fixed, and why?

Opportunities: biggest problem
Equity of access based on need not ability to pay.

24. What do you think of the current TGA regulatory framework around medicine shortages and discontinuations?

Improvement: TGA regulatory framework
Entire supply chain needs to be considered, rather than fragmented approach with different agencies responsible for different aspects.

25. Do you have any suggestions about how to improve medicine shortages and discontinuations in Australia (i.e., what does good management of medicine shortages and discontinuations look like for you)?

Opportunities: suggestions
Consider support for local manufacture so we can guarantee on-going supply for Australians.

26. Do you have any further comments about medicine shortages and discontinuations in Australia?

Opportunities: further comments
Essential medicines should not be used as a source of profit but considered as a government utility and guarantee to our people. We may be able to provide secure supply for our Pacific neighbours.

Consent

27. I consent to the collection, use or disclosure of my personal information as set out in the privacy notice and select the following option regarding the publication of my submission:

Please select one item
(Required)
Radio button: Ticked Publish my response, including both my name and organisation's name
Radio button: Unticked Publish my response, without my name but including my organisation's name
Radio button: Unticked Publish my response, without my name or my organisation's name (anonymously)
Radio button: Unticked Do not publish my response